119 related articles for article (PubMed ID: 38616380)
21. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
Amiot A; Serrero M; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Vuitton L; Viennot S; Bouguen G; Abitbol V; Fumery M; Gagniere C; Bouhnik Y;
Aliment Pharmacol Ther; 2019 Jul; 50(1):40-53. PubMed ID: 31165509
[TBL] [Abstract][Full Text] [Related]
22. Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy.
Engström J; Lönnkvist M; Befrits R; Ljung T; Diaz-Tartera H; Holst M; Hellström PM
Scand J Gastroenterol; 2019 Sep; 54(9):1081-1088. PubMed ID: 31499013
[No Abstract] [Full Text] [Related]
23. Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
Macaluso FS; Fries W; Renna S; Viola A; Muscianisi M; Cappello M; Guida L; Siringo S; Camilleri S; Garufi S; Privitera AC; Belluardo N; Giangreco E; Bertolami C; Vassallo R; Rizzuto G; Orlando R; Ventimiglia M; Orlando A;
United European Gastroenterol J; 2020 Nov; 8(9):1045-1055. PubMed ID: 32772830
[TBL] [Abstract][Full Text] [Related]
24. Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.
Engel T; Ungar B; Yung DE; Ben-Horin S; Eliakim R; Kopylov U
J Crohns Colitis; 2018 Jan; 12(2):245-257. PubMed ID: 29077833
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
Kopylov U; Ron Y; Avni-Biron I; Koslowsky B; Waterman M; Daher S; Ungar B; Yanai H; Maharshak N; Ben-Bassat O; Lichtenstein L; Bar-Gil Shitrit A; Israeli E; Schwartz D; Zittan E; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
Inflamm Bowel Dis; 2017 Mar; 23(3):404-408. PubMed ID: 28178003
[TBL] [Abstract][Full Text] [Related]
26. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.
Christensen B; Colman RJ; Micic D; Gibson PR; Goeppinger SR; Yarur A; Weber CR; Cohen RD; Rubin DT
Inflamm Bowel Dis; 2018 Mar; 24(4):849-860. PubMed ID: 29562271
[TBL] [Abstract][Full Text] [Related]
27. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
Moens A; Verstockt B; Alsoud D; Sabino J; Ferrante M; Vermeire S
Inflamm Bowel Dis; 2022 Aug; 28(8):1135-1142. PubMed ID: 34751766
[TBL] [Abstract][Full Text] [Related]
28. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
29. Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab.
Dulai PS; Wong ECL; Reinisch W; Colombel JF; Marshall JK; Narula N
Inflamm Bowel Dis; 2022 Oct; 28(10):1555-1564. PubMed ID: 34967397
[TBL] [Abstract][Full Text] [Related]
30. Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease.
Alric H; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
Inflamm Bowel Dis; 2022 Feb; 28(2):218-225. PubMed ID: 33847351
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
32. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Mocci G; Tursi A; Maconi G; Cataletti G; Mantia B; Serio M; Scarcelli A; Pagnini C; Graziani MG; Di Paolo MC; Pranzo G; Luppino I; Paese P; Elisei W; Monterubbianesi R; Faggiani R; Ferronato A; Perini B; Savarino E; Onidi FM; Binaghi L; Usai Satta P; Schiavoni E; Napolitano D; Scaldaferri F; Pugliese D; Pica R; Cocco A; Zippi M; Rodino S; Sebkova L; Rocco G; Sacchi C; Zampaletta C; Gaiani F; De Angelis G; Kayali S; Fanigliulo L; Lorenzetti R; Allegretta L; Scorza S; Cuomo A; Donnarumma L; Della Valle N; Sacco R; Forti G; Antonelli E; Bassotti G; Iannelli C; Luzza F; Aragona G; Perazzo P; Lauria A; Piergallini S; Colucci R; Bianco MA; Meucci C; Giorgetti G; Clemente V; Fiorella S; Penna A; De Medici A; Picchio M; Papa A
Expert Opin Biol Ther; 2023 Mar; 23(3):293-304. PubMed ID: 36843568
[TBL] [Abstract][Full Text] [Related]
33. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.
Dulai PS; Amiot A; Peyrin-Biroulet L; Jairath V; Serrero M; Filippi J; Singh S; Pariente B; Loftus EV; Roblin X; Kane S; Buisson A; Siegel CA; Bouhnik Y; Sandborn WJ; Lasch K; Rosario M; Feagan BG; Bojic D; Trang-Poisson C; Shen B; Altwegg R; Sands BE; Colombel JF; Carbonnel F;
Aliment Pharmacol Ther; 2020 Mar; 51(5):553-564. PubMed ID: 31867766
[TBL] [Abstract][Full Text] [Related]
34. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
[TBL] [Abstract][Full Text] [Related]
35. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.
Dragoni G; Bagnoli S; Le Grazie M; Campani C; Rogai F; Manetti N; Bensi C; Macrì G; Galli A; Milla M
J Dig Dis; 2019 May; 20(5):235-242. PubMed ID: 30927309
[TBL] [Abstract][Full Text] [Related]
37. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
Bergqvist V; Holmgren J; Klintman D; Marsal J
Aliment Pharmacol Ther; 2022 Jun; 55(11):1389-1401. PubMed ID: 35470449
[TBL] [Abstract][Full Text] [Related]
38. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T
Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939
[No Abstract] [Full Text] [Related]
39. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
[TBL] [Abstract][Full Text] [Related]
40. VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY.
Perin RL; Damião AOMC; Flores C; Ludvig JC; Magro DO; Miranda EF; Moraes AC; Nones RB; Teixeira FV; Zeroncio M; Kotze PG
Arq Gastroenterol; 2019; 56(3):312-317. PubMed ID: 31633731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
